Tranexamic acid

Tranexamic acid (CAS 701-54-2), also known as AMCA, is a synthetic lysine derivative supplied as a racemic mixture of cis and trans isomers. It functions as an antifibrinolytic agent by competitively blocking plasminogen binding sites, thereby inhibiting fibrin clot breakdown. No E-code designation applies to this substance.

In pharmaceutical manufacturing, tranexamic acid serves as an active pharmaceutical ingredient in haemostatic formulations designed to reduce excessive bleeding in surgical and trauma settings. It is also used as a reference standard and synthetic intermediate in dermatological drug development, where its melanin-suppressing mechanism supports skin-brightening therapeutic products.

Tranexamic acid is available in pharmaceutical-grade solid form, manufactured in compliance with Ph.Eur. monograph specifications. It falls under REACH regulation and is classified within HS code 2922.49.8000 for customs purposes. Procurement teams should confirm certificate of analysis documentation and GMP status with the supplying facility prior to order.